

Biomarkers

Part 1: Technologies & Applications

By

Prof. K.K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor+ 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. The following Jain PharmaBiotech reports are relevant to biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Handbook of Neuroprotection" (Springer 2011), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015).

November 2017
Copyright © 2017 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	27
1. Introduction	29
Definitions	29
Historical aspects of biomarkers	29
Classification of biomarkers	30
Biomarker as a response to therapeutic intervention	31
Pharmacokinetic/pharmacodynamics biomarkers	31
Predictive biomarkers	31
Valid biomarkers	32
Types of biomarkers	33
Genes as biomarkers	33
<i>Silent gene mutations</i>	33
Epigenetic biomarkers	33
Proteins as biomarkers	34
<i>Proteomics</i>	34
DNA biomarkers	35
Mitochondrial DNA	35
<i>Mitochondrial mutations</i>	35
RNA biomarkers	35
<i>Transcriptomics</i>	36
<i>MicroRNAs</i>	37
Metabolomics	37
Glycomics	37
Single nucleotide polymorphisms	38
<i>Haplotyping</i>	38
Cell biomarkers of disease	39
Stem cell biomarkers	39
<i>Association of stem cell biomarkers with disease</i>	39
<i>Cancer stem cell biomarkers</i>	40
<i>Endoglin as a functional biomarker of stem cells</i>	40
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells</i>	40
<i>Protein expression profile as biomarker of stem cells</i>	40
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs</i>	41
<i>SSEA-4 as biomarker of MSCs</i>	41
Gaseous mediators as biomarkers of disease	41
Autoantibodies as biomarkers of autoimmune diseases	41
Comparison of various types of biomarkers	42
Biomarkers and systems biology	42
Systems biology approach to biomarker identification	44
Relation of biomarkers to other technologies and healthcare	44
Biomarkers and translational medicine	45
Role of biomarkers in monitoring of diseases	46
Limitations of use of biomarkers in healthcare	46
2. Technologies for Discovery of Biomarkers	47
Introduction	47
The ideal biomarker	47
Genomic technologies	47
Gene expression	47
<i>Whole genome expression array</i>	48
<i>Gene expression profiling on whole blood samples</i>	49
<i>Profiling gene expression patterns of white blood cells</i>	49
Tissue microarrays for study of biomarkers	49
Technologies for detection of miRNAs as biomarkers	50
Microarrays for analysis of miRNA gene expression	50
<i>Microarrays vs quantitative PCR for measuring miRNAs</i>	51
Point-of-care detection of circulating miRNAs as biomarkers	51
Epigenomic technologies	51
Discovery of methylation biomarkers	52
Proteomic technologies	53
2D GE	54
ProteoCarta® integrated proteomics discovery platform	54
Isotope-coded affinity tags	55
Liquid chromatography-MS/MS	55
Lucid Proteomics System	56
Magnetics beads for protein biomarker discovery	56
MASstermind™	56

Combined analysis of protein and nucleic-acid biomarkers.....	57
Mass spectrometry	57
2D PAGE and mass spectrometry	58
Imaging mass spectrometry	58
MALDI mass spectrometry for biomarker discovery	59
Quantitative tandem MS	59
Single-molecule mass spectrometry using a nanopore	60
Requirements for MS-based proteomic biomarker development	60
Nucleic Acid Programmable Protein Array	60
Protein tomography.....	61
Protein biochips/microarrays and biomarkers.....	61
Antibody array/affinity proteomics-based biomarker discovery.....	61
Detection of biomarkers using peptide array technology.....	63
ProtoArray®.....	63
Protein nanobiochip	63
Gene expression microarray data as a source of protein biomarkers	64
Quantification of protein biomarkers.....	64
Multiple reaction monitoring assays	64
Real-time PCR for quantification of protein biomarkers.....	65
CYTOF for quantification of biomarkers	65
Search for biomarkers in body fluids.....	66
Challenges and strategies for discovery of protein biomarkers in plasma	66
Technologies for removal of highly abundant proteins in blood.....	66
3D structure of CD38 as a biomarker.....	67
BD™ Free Flow Electrophoresis System.....	67
Isotope tags for relative and absolute quantification	68
Plasma protein microparticles as biomarkers	68
Proteome partitioning	69
Stable isotope tagging methods	69
Technology to measure both the identity and size of the biomarker	70
Selected reaction monitoring MS	70
Targeted MS for verification of biomarkers	70
Biomarkers in the urinary proteome	71
Peptides as biomarkers of disease.....	72
Analysis of peptides in bodily fluids	72
Antibody biomarker discovery via evolution of peptides	73
Serum peptidome patterns.....	73
SISCAPA method for quantitating proteins and peptides in plasma	74
Comparison of proteomic profiling technologies for discovery of biomarkers	74
Verification for interlaboratory reproducibility of protein biomarkers	74
Significance of similar protein biomarkers in different tissues	75
Glycomic technologies	76
Cellular glycomics for discovery of cellular biomarkers	76
Metabolomic technologies.....	76
Genome-wide association studies for identification of metabolic biomarkers	77
Genetic influences on human blood metabolites	77
Lipid profiling	78
Mass spectrometry for discovery of metabolic biomarkers in plasma.....	78
Role of metabolomics in biomarker identification and pattern recognition	79
Urinary profiling by capillary electrophoresis.....	79
Validation of biomarkers in large-scale human metabolomics studies.....	79
Lipidomics.....	79
Disease biomarkers in breath	80
Portable breath test for volatile organic compounds.....	80
Detection of breath biomarkers by sensation technology	81
Detection of breath biomarkers by nanosensors.....	81
Detection of breath biomarkers optical frequency comb spectroscopy	81
Detection of breath biomarkers by infrared absorption spectroscopy.....	82
Detection of biomarkers by electronic nose	82
Fluorescent indicators for biomarkers	82
Molecular imaging technologies.....	83
Computer tomography.....	83
Magnetic resonance imaging.....	83
Positron emission tomography.....	84
Advantages of imaging biomarkers.....	84
Monitoring in vivo gene expression by molecular imaging.....	84
Molecular imaging in vivo as a biomarker	85
Challenges and future of molecular imaging	86
Basic research in molecular imaging	86
Imaging intracellular NADH as a biomarker of disease	86
Devices for molecular imaging	86

<i>Imaging biomarkers in clinical trials</i>	86
<i>Molecular imaging in clinical practice</i>	87
Nuclear magnetic resonance	87
Chemical derivatization to enhance biomarker detection by NMR	87
Fluxomics by using NMR	88
Nanobiotechnology	88
Dip Pen Nanolithography	88
Nanomaterials for biolabeling	89
<i>Quantum dot molecular labels</i>	90
<i>Bioconjugated QDs for multiplexed profiling of biomarkers</i>	90
<i>Magnetic nanotags for multiplex detection of biomarkers</i>	90
Nanoparticles for molecular imaging	91
Nanoparticles for discovering biomarkers	91
Nanoproteomics and biomarkers	92
<i>High-field asymmetric waveform ion mobility mass spectrometry</i>	92
Nanosensors for measuring biomarkers in blood	92
Nanobiochip sensor technique for analysis of oral cancer biomarkers	92
Future prospects of application of nanobiotechnology for biomarkers	93
Bioinformatics	93
Biomarker Workflow Guide	93
Analysis of microarray data for selecting useful biomarkers	94
Role of bioinformatics in discovery of protein biomarkers	94
Role of bioinformatics in detection of cancer biomarkers	95
Biomarker databases	95
Gene networks as biomarkers	96
Role of bioinformatics in integrating various data and biomarker discovery	96
Evaluation of biomarker studies	96
3. Biomarkers and Molecular Diagnostics	99
Introduction	99
Molecular diagnostic technologies	99
Polymerase chain reaction	99
<i>Amplification</i>	99
<i>Target selection</i>	100
<i>Detection of amplified DNA</i>	100
<i>Limitations of PCR</i>	100
Real-time PCR systems	101
<i>Limitations of real-time PCR</i>	101
<i>Future applications of real-time qPCR</i>	102
<i>Real-time qPCR for quantification of circulating mtDNA</i>	102
Combined PCR-ELISA	102
Non-PCR methods	103
<i>Linked Linear Amplification</i>	103
Transcription mediated amplification	103
Rapid analysis of gene expression	103
WAVE nucleic acid fragment analysis system	104
DNA probes with conjugated minor groove binder	104
Rolling circle amplification technology	105
<i>Gene-based diagnostics through RCAT</i>	105
<i>RCAT-immunodiagnosics</i>	106
<i>RCAT-biochips</i>	106
<i>RCAT-pharmacogenomics</i>	106
Circle-to-circle amplification	106
Biochips and microarrays	107
<i>Applications of biochips/microarrays</i>	107
<i>Role of biochip/microarrays in discovery of biomarkers</i>	108
Biomarkers and high throughput molecular screening	108
Detection and expression profiling of miRNA	109
Real-time PCR for expression profiling of miRNAs	109
Use of LNA to explore miRNA	109
Microarrays for analysis of miRNA gene expression	109
4. Biomarkers for Drug Discovery & Development	111
Introduction	111
Biomarker technologies for drug discovery	111
Proteomics-based biomarkers for drug discovery	111
Chemoproteomics	112
<i>Activity-based chemical proteomics</i>	112
Transcriptomics for drug discovery	112
Metabolomics for drug discovery	113
Biomarkers and drug safety	113

Biomarkers of adverse drug reactions	113
Applications of biomarkers in drug safety studies	114
Genomic technologies for toxicology biomarkers	114
Proteomic technologies for toxicology biomarkers	115
Metabonomic technologies for toxicology biomarkers	115
Integration of genomic and metabonomic data to develop toxicity biomarkers	115
Toxicology studies based on biomarkers	116
<i>Biomarkers of hepatotoxicity</i>	117
<i>Biomarkers of nephrotoxicity</i>	118
<i>Cardiotoxicity</i>	119
<i>Neurotoxicity</i>	120
Applications of biomarkers for drug development.....	120
Application of metabonomics/metabolomics for drug development	121
Application of biomarkers by the pharmaceutical companies	122
Biomarkers in clinical trials.....	123
<i>NIH recommendations on the use of biomarkers in clinical trials</i>	123
<i>Advantages of biomarkers for drug development.....</i>	<i>124</i>
<i>Limitations and problems with use of biomarkers in clinical trials</i>	<i>125</i>
Development of static and dynamic biomarkers	125
Molecular imaging as a biomarker in drug development	126
<i>Molecular imaging in preclinical studies</i>	<i>126</i>
<i>Molecular imaging in clinical trials</i>	<i>127</i>
<i>Prospects of molecular imaging in drug discovery and development</i>	<i>128</i>
Pharmacogenomic biomarker information in drug labels.....	128
Role of biomarkers in vaccine development	129
Role of biomarkers in relation to stage of drug discovery and development	129
Role of pharmacokinetic/pharmacodynamic biomarkers in drug development	129
Role of biomarkers for drug development in cardiovascular disorders	130
Role of biomarkers for drug development in neurological disorders.....	131
Significance of biomarkers in drug development	131
Organizations & resources for biomarker-based drug development.....	131
Biomarker Alliance	132
Biomarkers Consortium	132
Molecular Libraries and Imaging Roadmap of NIH	133
Rare Diseases Clinical Research Consortia	134
Future of biomarker-based drug development	134
5. Role of Biomarkers in Healthcare.....	136
Introduction.....	136
Biomarkers of inflammation.....	137
ESR and CRP as biomarkers of inflammation	137
Metabolic biomarkers of inflammation.....	138
YKL-40 as a biomarker inflammation and predictor of mortality	138
Biomarkers of allergic disorders	138
Biomarkers of oxidative stress.....	139
1,4-dihydroxynonane-mercaptopic acid	139
Oxidized phospholipids	139
Oxidative DNA damage	140
Proteins as biomarkers of oxidative stress in diseases.....	140
Testing for oxidative stress	140
Biomarkers of hypoxia	141
Pathophysiology of hypoxia	141
Hypoxia inducible factor as biomarker of hypoxia and response to oxygenation	141
Identification of hypoxia biomarkers from exhaled breath	141
Metabolic biomarkers of hypoxia	142
Biomarkers of liver disease.....	142
Breath biomarkers of liver disease	142
Biomarkers of liver injury.....	142
Fibrosis and cirrhosis of liver	143
FibroMax.....	143
Hepatic encephalopathy	143
miRNA biomarkers of liver disease	144
Viral hepatitis B and C	144
<i>Biomarkers of hepatitis C</i>	<i>144</i>
<i>Biomarkers of hepatitis B</i>	<i>145</i>
Biomarkers of pancreatitis	145
Biomarkers of renal disease.....	146
Biomarkers of lupus nephritis	146
Biomarkers of diabetic nephropathy	147
Cystatin C as biomarker of glomerular filtration rate (GFR)	147
Estimated GFR and albuminuria as biomarkers of chronic kidney disease	147

Proteomic biomarkers of acute kidney injury	148
Symmetric dimethylarginine as biomarker of chronic kidney disease in dogs	148
Troponin-T as a biomarker for predicting end-stage renal disease	148
Biomarkers in pediatrics	148
Pediatric critical care	148
Biomarkers of acute kidney injury in children	149
Biomarkers of miscellaneous disorders	149
Biomarkers of carbon monoxide poisoning	149
Biomarkers of Castleman disease	149
Biomarkers of erectile dysfunction	150
Biomarkers of fever	150
Biomarkers of heat stroke	151
Biomarkers of hyponatremia	151
Biomarkers of inflammatory bowel disease	151
Biomarkers of radiation injury	152
Biomarkers for prediction of all-cause mortality	153
Biomarkers common to multiple diseases	153
Nasal nitric oxide as a biomarker of response to rhinosinusitis therapy	154
Biomarkers of gene-environmental interactions in human disease	154
Application of biomarkers in animal health	155
6. Biomarkers in Metabolic Disorders	158
Biomarkers of acute intermittent porphyria	158
Liver X receptors	158
Biomarkers of diabetes mellitus	158
<i>β-cell function as biomarker of diabetes</i>	<i>160</i>
<i>Biomarkers of hyperglycemia</i>	<i>160</i>
<i>Biomarkers of diabetes-associated oxidative stress</i>	<i>160</i>
<i>Biomarkers of inflammation associated with diabetes</i>	<i>160</i>
<i>Biomarkers of renal complications in diabetes mellitus type 2</i>	<i>161</i>
<i>Biomarkers of diabetes</i>	<i>161</i>
<i>Biomarkers of prediabetes</i>	<i>161</i>
<i>Biomarkers of insulin resistance</i>	<i>161</i>
<i>Glycosylated hemoglobin in diabetes mellitus</i>	<i>162</i>
<i>Glycated albumin as a biomarker of diabetes mellitus</i>	<i>162</i>
<i>Low C-peptide as a biomarker of complications of diabetes type 1</i>	<i>162</i>
<i>Personalized management of diabetes mellitus based on biomarkers</i>	<i>163</i>
Biomarkers of metabolic syndrome	163
<i>Adiponectin</i>	<i>163</i>
<i>Cystatin C</i>	<i>164</i>
<i>Human plasma lipidome</i>	<i>164</i>
<i>Neurotensin as biomarker of obesity</i>	<i>165</i>
7. Biomarkers in Immune Disorders	168
Introduction	168
Biomarkers relevant to organ transplantation	168
Biomarkers of graft versus host disease	168
Biomarkers of renal allograft failure	169
Biomarkers of renal transplant tolerance	170
Biomarkers of lung transplant rejection	171
Biomarkers of GVHD following transplantation of hematopoietic cells	171
Plasma biomarkers of response to therapy of GVHD	171
Systemic lupus erythematosus	172
Adiponectin as biomarker of SLE	172
Current management and need for biomarkers of SLE	172
Role of collaborative efforts and databases of SLE biomarkers	173
C4d-bearing reticulocytes	173
CB-CAPS	173
Epigenetic biomarkers of SLE	173
Genetic loci of SLE	174
HMGB1	174
Biomarkers of systemic sclerosis	174
8. Biomarkers of Musculoskeletal Disorders	176
Introduction	176
Muscle disorders	176
Biomarkers of muscle fatigue during exercise	176
Biomarkers of mitochondrial content in skeletal muscle	176
Idiopathic inflammatory myopathies	177
Rheumatoid arthritis	177
Assays for biomarkers of RA	178

Biomarkers for personalizing therapy of rheumatoid arthritis	178
Circulating cytokines in RA	179
Epigenetic biomarkers of rheumatoid arthritis	179
miRNA biomarkers in RA	179
Serum CRP in RA	180
Biomarkers of spondylarthritis.....	180
Biomarkers of axial spondyloarthritis	181
Biomarkers of psoriatic arthritis	181
Osteoarthritis.....	181
Molecular pathophysiology of OA.....	182
Biomarkers of osteoarthritis	182
Assays for biomarkers of OA.....	183
Biomarkers of OA	183
Concluding remarks and future prospects of biomarkers of OA.....	184
Biomarkers of osteoporosis	184
Assays for detection of biomarkers of osteoporosis.....	184
Bone imaging with quantitative CT and MRI	185
Circulating miRNAs as biomarkers of osteoporosis	185
Dual x-ray absorptiometry	186
Utility of biomarkers of osteoporosis.....	186
Biomarkers of osteonecrosis.....	186
Osteonecrosis in Gaucher's disease	186
9. Biomarkers of Infectious Diseases.....	188
Introduction.....	188
Technologies for discovery of biomarkers of infection	188
Chemokines as biomarkers of infection	188
Endotoxin as biomarker of infection.....	188
Proteomics for discovering biomarkers of infections	188
Soluble urokinase plasminogen activator receptor	189
Sepsis	189
Biomarkers of sepsis	190
<i>Circulating CPS-1 as biomarkers of organ damage in sepsis.....</i>	<i>191</i>
<i>CoQ10 level reduction in septic shock</i>	<i>191</i>
<i>Multibiomarker-based outcome risk stratification of septic shock</i>	<i>192</i>
<i>Nitric oxide as a biomarker of sepsis.....</i>	<i>192</i>
<i>SuPAR as a biomarker of sepsis</i>	<i>192</i>
Systemic inflammatory response syndrome	193
Tuberculosis	193
Conventional diagnosis of tuberculosis	194
Molecular diagnostics for tuberculosis	194
Biomarkers for tuberculosis	194
Biomarkers of pulmonary tuberculosis in the breath	195
Biomarkers of viral infections	195
Viral hepatitis	195
Biomarkers of SARS	197
Biomarkers of HIV	198
Biomarkers in parasitic infections.....	199
Role of biomarkers in malaria	199
Identification of biomarkers in Schistosomiasis infections	199
Diagnostic & therapeutic applications of biomarkers of infections.....	200
Biomarkers to discriminate bacterial from nonbacterial respiratory infections.....	200
Procalcitonin as a guide to antibiotic therapy in infections	200
10. Biomarkers of Genetic Disorders.....	202
Introduction.....	202
Biomarkers of Down's syndrome	202
Biomarkers of muscular dystrophy	202
Biomarkers of phenylketonuria.....	203
Genetic biomarkers of psoriasis.....	203
Biomarkers of lysosomal storage disorders	204
Biomarkers of Niemann-Pick disease	204
<i>Bile acids as biomarkers for the early diagnosis of NPD.....</i>	<i>204</i>
<i>Cholesterol oxidation products as biomarkers of NPD.....</i>	<i>204</i>
Biomarkers of mucopolysaccharidoses	205
<i>Proteomic technologies for biomarkers of MPS</i>	<i>205</i>
<i>Glycan-based biomarkers for MPS</i>	<i>206</i>
<i>Biomarkers of LSD</i>	<i>206</i>
<i>Prenatal diagnosis of LSD.....</i>	<i>206</i>
Biomarkers of Fabry's disease	207

11. Biomarkers of Aging	208
Introduction.....	208
Biomarkers of biological age.....	209
Gene variants as determinants of biological age.....	210
Gene expression profiles for calculating transcriptomic age	210
Biomarkers of healthy aging	210
Biomarkers of longevity	211
Healthy aging index	211
Effect of calorie restriction on biomarkers of longevity	211
Biomarkers as predictors of mortality with aging	211
Genetic biomarkers of aging	212
Genetic signatures of longevity	212
Low serum thyroid hormone level as biomarker of longevity	212
Metabolomic biomarkers of aging	213
Mitochondrial mutations as biomarkers of aging	213
Protein biomarkers of aging.....	213
Carbamylated proteins as biomarkers of aging.....	213
Proteomic biomarkers of muscle aging.....	214
Role of humanin in age-related diseases	214
Role of bioinformatics in search for biomarkers of aging	214
Aging biomarkers in a genetically homogeneous population.....	215
Telomere attrition as aging biomarker	215
12. Nutritional Biomarkers.....	216
Introduction.....	216
Biomarkers of Nutrition for Development project	216
Biomarkers in nutritional epidemiology	216
Biomarkers of nutritional status	217
Ferritin as biomarker of nutritional status.....	217
Folate biomarkers related to nutritional health status	218
Iodine as biomarker of nutritional status	218
Zinc as a biomarker of nutritional status	219
Biomarkers of branched chain amino acid status	219
Biomarkers of caloric restriction	219
Biomarkers of malnutrition	219
Maternal nutrition during early pregnancy causes epigenetic changes	220
Proteomic biomarkers and nutrition	220
Vitamin deficiency as biomarker of disease	220
Vitamin A biomarkers	220
Vitamin B12 deficiency	221
Vitamin D deficiency as a biomarker of disease	222
Role of biomarkers in the development of personalized nutrition	222
13. Biomarkers of Cancer.....	224
Introduction.....	224
The ideal biomarker for cancer	224
Biomarkers and hallmarks of cancer	225
Single vs multiple biomarkers of cancer	225
Types of cancer biomarkers	226
miRNAs as biomarkers in cancer	226
<i>Diagnostic value of miRNA in cancer</i>	<i>228</i>
Biomarkers of epigenetic gene silencing in cancer	228
<i>5-hydroxymethylcytosine as a biomarker of cancer</i>	<i>229</i>
Carcinoembryonic antigen	229
Circulating cancer biomarkers.....	229
<i>Circulating tumor cells as cancer biomarkers</i>	<i>229</i>
<i>Circulating nucleic acids as potential biomarkers of cancer</i>	<i>230</i>
<i>Circulating exosomes and microvesicles as biomarkers of cancer</i>	<i>230</i>
<i>Circulating miRNAs for cancer detection</i>	<i>230</i>
DNA repair biomarkers	231
HER3 as biomarker of cancer.....	231
Immunologic and inflammation biomarkers of cancer	231
Metastatic cancer biomarkers	232
Molecular diagnostic techniques for cancer	232
Technologies for detection of cancer biomarkers	234
Genomic technologies for cancer biomarkers	234
<i>Biomarkers of PTEN tumor suppressor gene status</i>	<i>234</i>
<i>Cold-PCR</i>	<i>234</i>
<i>ddPCR for detection of cancer biomarkers in cell free plasma DNA.....</i>	<i>235</i>
<i>Digital karyotyping for cancer biomarkers</i>	<i>235</i>
<i>Genome analysis at the molecular level</i>	<i>235</i>

<i>KRAS as a biomarker of cancer</i>	236
<i>LigAmp for detection of gene mutations in cancer</i>	236
<i>Mitochondrial DNA as a cancer biomarker</i>	236
<i>Next generation sequencing for detection of cancer biomarkers</i>	237
<i>Telomerase as a biomarker of cancer</i>	238
Tissue microarrays for study of cancer biomarkers	238
Molecular fingerprinting of cancer	239
Proteomic technologies for detecting biomarkers of cancer	239
2D PAGE	240
<i>Antibody-based detection of protein biomarkers</i>	240
<i>Aptamer-based molecular probes for cancer biomarker discovery</i>	241
<i>Biomarkers of protein-drug interactions in cancer</i>	241
<i>Cancer immunomics to identify autoantibody signatures</i>	242
<i>Desorption electrospray ionization for detection of cancer biomarkers</i>	242
<i>Detection of circulating nucleosomes in serum of cancer patients</i>	242
<i>Detection of tumor biomarkers with ProteinChip technology</i>	243
<i>Glycoprotein biomarkers of cancer</i>	243
<i>HER-2/neu oncoprotein as biomarkers for cancer</i>	243
<i>Humoral proteomics</i>	244
<i>Laser capture microdissection</i>	244
<i>Membrane-type serine protease-1</i>	244
<i>Proteomic analysis of cancer cell mitochondria</i>	245
<i>Proteomic technologies for detection of autoimmune biomarkers</i>	245
SELDI-TOF MS.....	246
<i>Serum proteome analysis for early detection of cancer</i>	246
<i>Synthetic biomarker-based POC diagnostic for cancer</i>	246
<i>Triple-quadrupole MS for detection of mutant proteins</i>	246
<i>Targeted MS for validation of cancer biomarkers in plasma</i>	247
<i>Tissue proteomics for discovery of cancer biomarkers</i>	247
<i>VeraTag system for cancer biomarkers</i>	247
Metabolomic biomarkers of cancer	247
<i>Magnetic resonance for detecting metabolomics biomarkers of cancer</i>	248
<i>Choline phospholipid biomarkers of cancer</i>	248
<i>Hypoxia-inducible factor-1</i>	248
<i>Detection of drug resistance in cancer by metabolic profiling</i>	249
<i>Plasma free amino acids profiling in cancer</i>	249
<i>Urinary metabolomic biomarkers of cancer</i>	250
Epitomics for the early detection of cancer	250
Epigenetic biomarkers of cancer.....	250
<i>Detection of biomarkers of DNA methylation</i>	251
<i>Epigenomics Marker Machine for DNA methylation biomarkers</i>	252
<i>Histone deacetylase</i>	252
<i>MDScaTM microarray technology</i>	252
<i>Mucins as epigenetic biomarkers in epithelial cancers</i>	253
<i>PCR with bisulfite for detecting DNA methylation biomarkers in cancer</i>	253
<i>Detection of methylated DNA in serum and urine</i>	254
<i>Integrated platform for genetic and epigenetic analysis</i>	254
Nanobiotechnology for early detection of cancer to improve treatment	255
<i>Aptasensor for electrochemical detection of exosomes</i>	255
<i>Nanowire biosensors for detection of cancer biomarkers</i>	255
<i>NP-peptide complexes for detection of cancer biomarkers in urine</i>	256
Ultrasound radiation to enhance release of a tumor biomarker.....	256
In vivo imaging of cancer biomarkers	257
<i>Computer tomography</i>	257
<i>Optical systems for in vivo molecular imaging of cancer</i>	257
<i>Positron emission tomography</i>	257
<i>Imaging of tumor oxygenation and microvascular permeability by MRI</i>	258
<i>Xenon-enhanced MRI</i>	258
Kallikrein gene family and cancer biomarkers	258
Detection of CTCs as biomarkers of cancer	259
Applications of cancer biomarkers	260
Use of biomarkers for cancer classification	260
<i>Cancer classification using microarrays</i>	260
<i>Proteomic classification of cancer</i>	260
Use of biomarkers for early detection of cancer.....	260
Applications of biomarkers for cancer diagnosis	261
<i>Methylated DNA sequences as cancer biomarkers</i>	261
<i>MicroRNA expression profiling for diagnosis of human cancers</i>	262
<i>MUC4 as a diagnostic biomarker in cancer</i>	262
Applications of biomarkers for cancer diagnosis and therapy	262
<i>ARTS as a biomarker as well as a basis of anticancer drugs</i>	264

<i>Asparagine synthetase as biomarker for therapy with L-asparaginase</i>	264
<i>Peptide-based agents for targeting cancer biomarkers</i>	265
<i>PI3K mutations as a biomarker for use as a companion diagnostic</i>	265
Biomarkers for assessing efficacy of cancer therapy.....	265
<i>ERCC1-XPF expression as a biomarker of response to chemotherapy</i>	265
<i>P53 expression level as biomarker of efficacy of cancer gene therapy</i>	265
Biomarkers of angiogenesis for developing antiangiogenic therapy.....	266
<i>Biomarkers of response to antiangiogenic agents</i>	266
<i>Circulating endothelial cells as targets for antiangiogenic drugs</i>	266
<i>Imaging biomarkers for evaluation of antiangiogenic agents</i>	267
<i>Tumor endothelial biomarkers</i>	267
<i>VEGF signaling inhibitors as biomarkers</i>	268
<i>VEGF-PET imaging for analysis of angiogenic changes within a tumor</i>	268
Biomarkers of prognosis in cancer treatment.....	268
Biomarkers for monitoring cancer therapy.....	269
Biomarkers of drug resistance in cancer.....	269
<i>A systems approach to biomarkers of innate drug resistance</i>	269
<i>Epithelial membrane protein-1 as a biomarker of gefitinib resistance</i>	270
<i>Methylation biomarkers of drug resistance in cancer</i>	270
<i>STAT3 and resistance to cisplatin</i>	270
Biomarkers of radiation therapy for cancer.....	270
Role of biomarkers in drug development in oncology.....	271
Biomarker-based approval of an anticancer drug regardless of site.....	272
Biomarkers in plucked hair for assessing cancer therapy.....	272
Met receptors as targets for anticancer drugs.....	273
Molecular imaging of tumor as a guide to drug development.....	273
<i>Use of PET and SPECT to assess response to anticancer drugs</i>	273
<i>Use of MRI to assess response to anticancer drugs</i>	274
Role of biomarkers in phase I clinical trials of anticancer drugs.....	274
Safety biomarkers in oncology studies.....	275
Biomarkers according to organ/type of cancer.....	275
Bladder cancer biomarkers.....	275
<i>Detection of FGFR3 mutations in urine for diagnosis of bladder cancer</i>	275
<i>NMP22 BladderChek</i>	276
<i>Urinary telomerase as biomarker for detection of bladder cancer</i>	276
<i>Concluding remarks about biomarkers of urinary cancer</i>	276
Brain tumor biomarkers.....	276
<i>14-3-3zeta positive expression as a prognostic biomarker for GBM</i>	277
<i>ALDH1A3 as a biomarker of GBM</i>	277
<i>Biomarkers to predict response to EGFR inhibitors</i>	277
<i>Biomarkers for predicting recurrence of meningiomas</i>	278
<i>CD133 as biomarker of resistance to radiotherapy</i>	278
<i>Circulating microvesicles as biomarkers</i>	278
<i>CSF attractin as a biomarker of malignant astrocytoma</i>	278
<i>ELTD1 as a biomarker of gliomas</i>	279
<i>Methylation profiling of brain tumors</i>	279
<i>Metabolite biomarkers of brain tumors</i>	280
<i>miRNAs as biomarkers of brain tumors</i>	281
<i>MRI biomarker for response of brain tumor to therapy</i>	281
<i>Multigene predictor of outcome in GBM</i>	281
<i>Neuroimaging biomarkers combined with DNA microarray analysis</i>	282
<i>Proteomic analysis of CSF for identification of biomarkers for gliomas</i>	282
<i>Receptor protein tyrosine phosphatase β as biomarker of gliomas</i>	282
<i>Serum protein fingerprinting</i>	282
<i>VEGF-R2 as biomarker of angiogenesis in brain tumors</i>	283
<i>Future prospects of biomarkers of malignant gliomas</i>	283
Bone tumor biomarkers.....	283
<i>Cytogenetics for the study of bone and soft tissue tumors</i>	283
<i>Biomarkers of Ewing's tumors</i>	284
<i>Role of biomarkers in the diagnosis of bone tumors</i>	284
Breast cancer biomarkers.....	284
<i>Autoantibody biomarkers of breast cancer</i>	285
<i>Biomarkers of breast cancer in breath</i>	286
<i>Biomarkers for breast cancer in nipple aspiration fluid</i>	286
<i>Circulating tumor DNA as biomarker of breast cancer</i>	287
<i>Circulating exosomes as biomarkers of breast cancer</i>	287
<i>Flow cytometry for quantification of biomarker expression patterns</i>	287
<i>Plasma proteomics for biomarkers of breast cancer</i>	288
<i>Quantitative realtime PCR assays for biomarker validation</i>	288
<i>Cdk6 as a biomarker of breast cancer</i>	289
<i>Centromere protein-F</i>	289

Carbonic anhydrase IX.....	289
COX-2 as a biomarker of breast cancer.....	289
G88 as a biomarker of progression of ER+ breast cancer.....	290
Glycomic biomarkers of breast cancer.....	290
HER-2/neu oncoprotein.....	290
High mobility group protein A2.....	291
Hypermethylated genes as biomarkers of metastatic breast cancer.....	292
Lipocalin 2 as biomarker of breast cancer progression.....	292
Long intervening non-coding RNAs.....	292
Mammaglobin.....	293
miRNA biomarkers of breast cancer.....	293
p27 expression as biomarker for survival after chemotherapy.....	294
Podocalyxin.....	294
Proneurotensin and Proenkephalin.....	294
Proliferating cell nuclear antigen.....	295
Protein kinase C as a predictive biomarker of metastatic breast cancer.....	295
Retinoblastoma tumor suppressor gene as a biomarker.....	295
Riboflavin carrier protein.....	295
Risk of invasive cancer after diagnosis of ductal carcinoma in situ.....	296
Serum CA 15-3 as biomarker of prognosis in advanced breast cancer.....	296
Stage-specific embryonic antigen-3.....	296
Suppressor of deltex protein.....	297
Tumor microenvironment as biomarker of metastasis in breast cancer.....	297
Type III TGF- β receptor as regulator of cancer progression.....	297
Diagnostic tests based on breast cancer genes.....	298
Prognostic role of breast cancer genes.....	298
Protein biomarkers for breast cancer prevention.....	299
Biomarkers to evaluate efficacy of chemoprevention.....	299
Biomarkers of response to chemotherapy of breast cancer.....	300
Biomarker-guided decisions for breast cancer therapy.....	300
Concluding remarks and future prospects of breast cancer biomarkers.....	300
Cervical cancer biomarkers.....	301
Gastrointestinal cancer biomarkers.....	302
Esophageal cancer biomarkers.....	302
Gastric cancer biomarkers.....	302
Colorectal cancer biomarkers.....	303
Head and neck cancer.....	309
Leukemia biomarkers.....	310
Chromosome translocations in leukemias.....	311
DNA methylation biomarkers in leukemia.....	311
Gene mutations as biomarkers in leukemia.....	311
Molecular diagnostic techniques for leukemia.....	312
Proteomic technologies for discovering biomarkers of leukemia.....	312
Biomarkers of chronic lymphocytic leukemia.....	313
Biomarkers of chronic myeloid leukemia.....	313
Biomarkers of drug resistance in leukemia.....	314
Biomarkers of myelodysplastic syndromes.....	314
Lymphoma biomarkers.....	314
Liver cancer biomarkers.....	315
Biomarkers indicating lower risk of HCC in coffee drinkers.....	316
Metabonomic profiles discriminate HCC from liver cirrhosis.....	316
Urinary biomarkers of HCC.....	316
Lung cancer biomarkers.....	316
Autoantibodies as biomarkers in lung cancer.....	317
Biomarkers associated with neuroendocrine differentiation in NSCLC.....	318
Biomarkers of chronic inflammation in lung cancer.....	318
Biomarkers for predicting sensitivity to chemotherapy in lung cancer.....	319
Biomarkers for prediction of sensitivity to EGFR inhibitors.....	319
CTCs as biomarkers of lung cancer.....	320
Genomic biomarkers of lung cancer.....	321
Methylation biomarkers of lung cancer.....	321
miRNA biomarkers in lung cancer.....	322
Noninvasive detection of lung cancer using exhaled breath.....	322
Serum protein biomarkers of lung cancer.....	323
tNOX as biomarker of lung cancer.....	324
Tumor-derived DNA and RNA markers in blood.....	324
Volatile organic compounds in the exhaled breath.....	324
Malignant pleural mesothelioma.....	325
Melanoma biomarkers.....	325
Nasopharyngeal carcinoma biomarkers.....	327
Proteomic biomarkers of nasopharyngeal cancer.....	328

<i>miRNA biomarkers of nasopharyngeal carcinoma</i>	328
Oral cancer biomarkers	328
Ovarian cancer biomarkers.....	329
<i>3D microfluidic platform to assess multiple ovarian cancer biomarkers</i>	330
<i>CA125 as biomarker of ovarian cancer</i>	330
<i>Epitomics approach for ovarian cancer biomarkers in serum</i>	330
<i>FGF18 as a biomarker in ovarian cancer</i>	331
<i>Gene expression studies in ovarian cancer</i>	331
<i>HE4 protein in urine as a biomarker for ovarian cancer</i>	332
<i>Hematogenous metastasis of ovarian cancer</i>	332
<i>HtrA1 as a biomarker of response to chemotherapy in ovarian cancer</i>	332
<i>Mutation of genes in ovarian cancer</i>	332
<i>Serum biomarkers of ovarian cancer prognosis</i>	333
<i>TIM-3 as a biomarker of ovarian cancer</i>	333
<i>Multiplex assays for biomarkers of ovarian cancer</i>	333
<i>Concluding remarks on biomarker-based tests of ovarian cancer</i>	334
Pancreatic cancer biomarkers	334
<i>Discovery and validation of pancreatic cancer biomarkers</i>	335
<i>Cancer stem cells as biomarkers of pancreatic cancer</i>	336
<i>Circulating exosomes as biomarkers of pancreatic cancer</i>	336
<i>Histone modifications used as biomarkers in pancreatic cancer</i>	336
<i>miRNA biomarkers of pancreatic cancer</i>	337
<i>Macrophage inhibitory cytokine-1 as biomarker of pancreatic cancer</i>	337
<i>Proteomic biomarkers of pancreatic cancer</i>	338
<i>Concluding remarks on biomarkers of pancreatic cancer</i>	338
Parathyroid cancer biomarkers	338
Peripheral nerve tumors.....	339
<i>Biomarkers of neurofibromatosis</i>	339
Prostate cancer.....	339
<i>Adipose tissue-derived biomarkers of obesity-related prostate cancer</i>	340
<i>B7-H3 as biomarker of prostate cancer</i>	340
<i>Cancer genetics-guided biomarker signatures of prostate cancer</i>	341
<i>Detection of prostate cancer biomarkers in urine</i>	341
<i>Detection of prostatic intraepithelial neoplasia</i>	342
<i>Epigenetic biomarkers of prostate cancer</i>	342
<i>Exosomes as biomarkers of prostate cancer</i>	343
<i>Gene expression analysis of prostate cancer</i>	343
<i>Genetic biomarkers of prostate cancer</i>	344
<i>Identification of prostate cancer mRNA biomarkers</i>	344
<i>Kallikreins as biomarkers of prostate cancer</i>	344
<i>LCM for diagnosis of prostate cancer</i>	345
<i>Microarray for diagnosis of prostate cancer</i>	345
<i>miRNA biomarkers of prostate cancer</i>	346
<i>Prostate cancer biomarkers in semen</i>	347
<i>PSA as biomarker of prostate cancer</i>	347
<i>ProPSA as biomarker of prostate cancer</i>	348
<i>Prostate Health Index</i>	348
<i>Prostasomes in blood as biomarker of prostate cancer</i>	348
<i>PSMA as biomarker of prostate cancer</i>	348
<i>Sarcosine as a metabolic biomarker of prostate cancer</i>	349
<i>Silenced CDH13 gene as a biomarker of cancer</i>	349
<i>Serum-protein fingerprinting</i>	349
<i>Concluding remarks on biomarkers of prostate cancer</i>	350
Renal cancer biomarkers.....	350
<i>Gene expression profile of RCC for biomarkers</i>	350
<i>miRNA biomarkers of renal cancer</i>	350
<i>Use of proteomics for detection of RCC biomarkers</i>	351
<i>Use of RCC biomarkers for prognosis and therapy</i>	351
Thyroid cancer biomarkers	352
<i>Detection of BRAF mutation</i>	352
<i>Gene expression biomarkers of thyroid cancer</i>	352
<i>miRNA biomarkers of thyroid cancer</i>	353
<i>Multiple endocrine neoplasia type 2B as risk factor for thyroid cancer</i>	353
Role of the NCI in cancer biomarkers	354
Future prospects for cancer biomarkers	355
Cancer biomarker research at academic institutions	355
Future challenges in the discovery of cancer biomarkers	355
14. Biomarkers of Disorders of the Nervous System	358
Introduction	358
Discovery of biomarkers for neurological disorders	358

Biomarker identification in the CSF using proteomics	359
Biomarker identification in the CSF using lipidomics	359
Cerebral microdialysis for the study of biomarkers of cerebral metabolism	360
Detection of protein biomarkers of CNS disorders in the blood	360
Genomic technologies for study of biomarkers of neurological disorders	360
Brain imaging for detection of biomarkers	361
Biomarkers of the aging brain.....	361
Cellular biomarker of aging of the brain	361
CSF F2-isoprostanes as biomarker of aging brain	361
IL-6 as a biomarker of cognitive impairment with aging	362
Protein aggregation as a biomarker of aging brain.....	362
Telomere shortening as a biomarker of aging brain and dementia	362
Data mining for biomarkers of neurological disorders	363
Antibodies as biomarkers in disorders of the nervous system	363
Biomarkers of neural regeneration	363
Biomarkers of disruption of blood-brain barrier.....	364
Biomarkers of neuroinflammation.....	364
Biomarkers of neurotoxicity.....	365
Glial fibrillary acidic protein as biomarker of neurotoxicity	366
Single-stranded DNA as a biomarker of neuronal apoptosis	366
Biomarkers of neurogenetic disorders	366
Charcot-Marie Tooth disease	367
Duchenne and Becker muscular dystrophy	367
Early-onset torsion dystonia	368
Fragile X syndrome	368
Genetic neurotransmitter disorders	369
Hereditary neuropathy with liability to pressure palsies.....	369
Hereditary metabolic storage disorders with neurologic manifestations	370
<i>Gaucher disease</i>	370
<i>Pompe's disease</i>	370
Mitochondrial disorders affecting the nervous system	370
Spinal muscular atrophy	371
<i>Biomarkers of SMA</i>	371
Biomarkers of neurodegenerative disorders	371
Biomarkers of dementia.....	372
Biomarkers of vascular dementia	372
Biomarkers of Alzheimer's disease	373
The ideal biomarker for AD.....	375
Methods for determining biomarkers of AD.....	375
<i>Gene expression patterns in AD</i>	375
<i>Magnetic resonance spectroscopy in AD</i>	376
<i>MicroRNAs as biomarkers of neurodegenerative disorders</i>	376
<i>MRI for biomarkers of AD</i>	377
<i>Nanotechnology to measure Aβ-derived diffusible ligands</i>	378
<i>PET scanning for biomarkers of AD</i>	378
<i>Simultaneous measurement of several biomarkers for AD</i>	380
<i>Targeting of chemokine receptor as biomarker for brain imaging</i>	380
Biomarkers of AD in CSF	381
<i>CSF sulfatide as a biomarker for AD</i>	381
<i>CSF Reelin as biomarker of AD</i>	381
<i>Monitoring of synthesis and clearance rates of Aβ in the CSF</i>	381
<i>Protein biomarkers of AD in CSF</i>	382
<i>Tau proteins in CSF</i>	383
<i>Tests for the detection of Aβ in CSF</i>	383
<i>Tests combining CSF tau and Aβ</i>	384
Blood biomarkers of AD	385
<i>A serum protein-based algorithm for the detection of AD</i>	385
<i>Amyloid precursor protein</i>	385
<i>Detection of aggregated misfolded proteins in the blood</i>	385
<i>Lipid biomarkers for preclinical detection of AD</i>	386
<i>Lymphocyte Proliferation Test</i>	386
<i>Metabolomic biomarker profiling</i>	386
<i>Plasma protein biomarkers of AD</i>	386
<i>Protein kinase C in red blood cells</i>	387
Urine tests for AD	387
A biomarker-based skin test for AD	388
Salivary biomarkers of AD.....	388
Applications of biomarkers of AD.....	388
<i>Biomarker changes in autosomal dominantly inherited AD</i>	388
<i>Correlation of imaging biomarkers with CSF biomarkers of AD</i>	389
<i>Genetic tests for AD</i>	389

<i>Humanin as a biomarker as well as neuroprotective in AD</i>	390
<i>Plasma biomarkers of drug response in AD</i>	390
<i>PredictAD project</i>	390
<i>TOMM40 gene and risk of AD</i>	391
<i>Use of biomarkers to predict AD in patients with MCI</i>	391
Concluding remarks about biomarkers for AD and future prospects	392
Biomarkers of Parkinson's disease	393
Autoantibodies as biomarkers of PD	394
Biomarkers of PD based on gene expression in blood.....	394
Cardiac denervation as a biomarker of PD	394
Genetic biomarkers of PD.....	394
Imaging biomarkers of PD	395
Metabolic brain networks as biomarkers.....	396
Metabonomic biomarker profile for diagnosis and monitoring of PD	396
Protein biomarkers of PD	396
<i>P11 protein as a biomarker of depression in PD</i>	397
Serum vitamin D as a biomarker of PD	397
Biomarkers of prodromal PD.....	398
Future needs for biomarkers of PD	398
Biomarkers of Huntington's disease	399
Genetic biomarker of HD progression	400
Quantitative MRI measurement of brain atrophy as biomarker of HD	400
Metabolic networks as biomarkers of preclinical Huntington disease	400
Biomarkers of Wilson's disease	401
Biomarkers of amyotrophic lateral sclerosis	401
ALS biomarker detection in blood vs CSF	402
Biomarkers of neuroinflammation in ALS	402
Genetic biomarkers of ALS	402
Imaging biomarkers of ALS	403
Metabolomic biomarkers of ALS	403
Proteomic biomarkers of ALS	404
Ideal biomarker of ALS	404
Future of biomarkers of ALS	404
HIV-1-associated neurocognitive disorders	405
Biomarkers of dementia in HIV-1-infected patients.....	405
Biomarkers of autoimmune encephalitis	405
Biomarkers of prion diseases	405
14-3-3 protein and tTau/P-Tau ratio.....	406
Bioluminescence imaging as a surrogate biomarker of prion infectivity	406
miRNAs as biomarkers of prion-induced neurodegeneration.....	406
Prion protein detection by real-time quaking-induced conversion	407
Prions in the urine of patients with variant CJD	407
Biomarkers of multiple sclerosis	407
Antibodies in multiple sclerosis	408
<i>Antibodies to galactocerebroside</i>	409
<i>Antibodies to myelin oligodendrocyte glycoprotein</i>	409
Brain N-acetylaspartylglutamate as biomarker of cognitive function in MS.....	409
Brain imaging biomarkers of multiple sclerosis.....	409
<i>MRI biomarkers of multiple sclerosis</i>	409
<i>Molecular imaging</i>	410
Biomarkers of response to therapy of multiple sclerosis	410
<i>DNA motifs in the blood as biomarkers of response to treatment</i>	410
<i>Gene expression</i>	411
<i>Lymphocyte subsets as biomarkers of therapeutic response</i>	412
<i>Neurofilaments</i>	412
<i>Vitamin D as predictor of activity and progression of MS</i>	412
CSF biomarkers in multiple sclerosis.....	412
CSF Cystatin C as a biomarker of multiple sclerosis	412
Detecting autoantibodies in multiple sclerosis	413
<i>Switch-associated protein 70 antibodies in multiple sclerosis</i>	413
Gelsolin as a biomarker of multiple sclerosis.....	413
Matrix metalloproteinases as biomarkers in multiple sclerosis	413
Oligoclonal bands as biomarkers of MS	414
Serum proteomic pattern analysis in multiple sclerosis	414
T cells as biomarkers of multiple sclerosis	414
Concluding remarks and future perspective for biomarkers of multiple sclerosis	414
Biomarkers of cerebrovascular disorders	415
Biomarkers of stroke	415
<i>Etiological biomarkers of ischemic stroke</i>	417
<i>Brain natriuretic peptide as a biomarker for cardioembolic stroke</i>	418
<i>Brain lactate and N-acetylaspartate as biomarkers of stroke</i>	418

CRP as biomarker of risk of stroke.....	418
CSF biomarkers in acute stroke.....	419
Gene expression in blood following ischemic stroke.....	419
Glutathione S-Transferase- π	419
Intercellular adhesion molecule 1 as biomarker of ischemic stroke.....	420
Lp-PLA2 and CRP as biomarkers for stroke.....	420
Matrix metalloproteinase-9.....	420
miRNAs as biomarkers of stroke.....	420
Neuroserpin polymorphisms as a biomarker of stroke.....	420
NMDA receptors as biomarkers of excitotoxicity in stroke.....	421
Nucleosomes as biomarkers of stroke.....	421
PARK7 and nucleoside diphosphate kinase A as biomarkers of stroke.....	421
Visinin-like protein 1.....	422
Biomarker panels for stroke.....	422
Future prospects for biomarkers of stroke.....	422
Biomarkers of cerebral vasospasm.....	423
Biomarkers of intracerebral hemorrhage.....	423
Biomarkers of hypoxic brain damage.....	424
Biomarkers of ischemic brain damage.....	424
D-dimer as a biomarker of cerebral venous thrombosis.....	424
Biomarkers of traumatic brain injury.....	425
Technologies for identification of biomarkers of TBI.....	425
Cerebral microdialysis for study of biomarkers of TBI.....	425
Proteomic technologies for biomarkers of TBI.....	426
Systemic biology approach for discovery of biomarkers of TBI.....	427
Biomarkers of TBI.....	427
A β as a biomarker of TBI.....	428
CCL11 as a biomarker of chronic traumatic encephalopathy.....	428
Diffusion tensor imaging in TBI.....	428
Glial fibrillary acidic protein as biomarker of TBI.....	428
Hyperphosphorylated axonal neurofilament protein.....	429
IL-6 and nerve growth factor as biomarkers of TBI.....	429
Myelin basic protein.....	429
Neurofilament heavy chain.....	429
Serum S100 β as biomarker of TBI.....	430
SNTF as a biomarker for predicting cognitive decline after mild TBI.....	430
Tau as biomarker of TBI.....	431
Ubiquitin C-terminal Hydrolase-L1.....	431
Biomarkers of inflicted TBI in infants.....	431
Biomarkers of concussion.....	432
Clinical applications of biomarkers of TBI.....	432
Biomarkers of CNS infections.....	433
Biomarkers of bacterial meningitis.....	433
Biomarkers of viral infections of CNS.....	433
Biomarkers of CNS HIV infection.....	433
CSF kynurenic acid level as a biomarker of tick-borne encephalitis.....	434
Biomarkers of epilepsy.....	434
Biochemical markers of epilepsy.....	435
Biomarkers of temporal lobe epilepsy.....	435
Biomarkers of drug-resistant epilepsy.....	435
Genetic epilepsies.....	436
Electrophysiological biomarkers of epilepsy.....	436
Imaging biomarkers of epilepsy.....	436
Protein biomarkers of inflammation in epilepsy.....	437
Biomarkers of normal pressure hydrocephalus.....	437
Biomarkers of pseudotumor cerebri.....	437
Biomarkers of retinal disorders.....	438
Biomarkers of age-related macular degeneration.....	438
Biomarkers of sleep disorders.....	439
Biomarker of excessive daytime sleepiness.....	439
Biomarkers of obstructive sleep apnea.....	439
Biomarkers of restless legs syndrome.....	440
Biomarkers of pain.....	440
Biomarkers of disorders with musculoskeletal pain.....	441
Biomarkers of neuropathic pain.....	441
Brain insular glutamate as biomarker of fibromyalgia.....	441
Biomarkers of visceral pain.....	441
Biomarkers of migraine.....	442
Biomarkers of myalgic encephalomyelitis/chronic fatigue syndrome.....	442
Biomarkers of psychiatric disorders.....	443
Anorexia nervosa.....	443

Attention-deficit hyperactivity disorder	444
Biomarkers of autism	444
<i>Epigenetics of ASD</i>	445
<i>Gastrointestinal microbiota disturbances and ASD</i>	445
<i>Genetic factors in ASD</i>	445
<i>Immune biomarkers of ASD</i>	445
<i>Metabolic disturbances in autism</i>	446
<i>Neurophysiological biomarkers</i>	446
<i>Role of oxidative stress in autism</i>	447
<i>Test for ASD based on a 55-gene expression panel</i>	447
<i>Umbilical cord biomarkers</i>	447
Biomarkers of bipolar disorder	447
Biomarkers of depression	448
<i>Biochemical biomarkers of depression</i>	449
<i>Biomarkers and response to antidepressant treatment</i>	449
<i>Cingulate cortex activity and response to antidepressants</i>	449
<i>Genetic biomarkers of response to antidepressants</i>	450
<i>Inflammatory biomarkers of depression and psychosis</i>	450
<i>P11 as a biomarker of depression</i>	450
<i>Panels of blood-based biomarkers for diagnosis of MDD</i>	450
<i>Plasma metabolomics for diagnosis of MDD</i>	451
<i>Post-partum depression</i>	451
Biomarkers of posttraumatic stress disorder	452
Biomarkers of psychosis	453
Biomarkers of schizophrenia	453
<i>Biomarkers of abnormalities of visual information processing</i>	454
<i>Genetic biomarkers of schizophrenia</i>	454
<i>Gene expression analysis of blood for biomarkers of schizophrenia</i>	454
<i>Metabolic biomarkers of schizophrenia</i>	454
<i>Proteomic studies for biomarkers of schizophrenia</i>	455
Biomarkers of suicide	455

15. Biomarkers of Cardiovascular Disorders 457

Epidemiology of cardiovascular disease 457

Biomarkers of cardiovascular diseases 457

Biomarkers of acute myocardial infarction 459

Genetic biomarkers of cardiovascular disorders 459

Methods for identification of cardiovascular biomarkers 461

Application of proteomics for biomarkers of cardiovascular disease 461

Targeted MS-based pipeline approach 461

Cardiovascular disease biomarker panel 462

Detection of biomarkers of myocardial infarction in saliva by a nanobiochip 462

Metabolomic technologies for biomarkers of myocardial ischemia 462

Imaging biomarkers of cardiovascular disease 462

Annexin A5 as an imaging biomarker of cardiovascular disease 463

Cardiovascular MRI 463

Cardiovascular hybrid imaging 463

Myocardial perfusion imaging 463

Implantable magnetic biosensors for detecting cardiac biomarkers 464

Applications of biomarkers of cardiovascular disease 464

Biomarkers for ischemic heart disease and myocardial infarction 464

Troponin 465

Natriuretic peptide 466

Copeptin 467

Creatine kinase muscle brain 468

miRNAs as biomarkers of acute coronary syndrome 468

Myoglobin 468

Fatty acid binding protein 468

Growth Differentiation Factor-15 469

High density lipoprotein 2 469

Cripto-1 as a biomarker of myocardial infarction 469

Cataract as a biomarker of ischemic heart disease 469

Plasma CD93 as a biomarker for coronary artery disease 470

Plasma fetuin-A levels and the risk of myocardial infarction 470

YKL-40 as an inflammatory biomarker in ischemic heart disease 470

Biomarkers of cardiomyopathy 470

miRNA biomarkers of peripartum cardiomyopathy 470

Takotsubo cardiomyopathy 471

Troponin T levels in hypertrophic cardiomyopathy 471

Biomarkers of heart failure 471

Annexin A5 for prognosis of heart failure 471

Angiogenesis biomarkers	472
β -2a protein as a biomarker of heart failure	472
Desmin	472
Galectin-3 as biomarker of acute heart failure	472
G protein-coupled receptor kinase-2 as biomarker of CHF	473
KIF6 gene as biomarker of heart failure	473
Metabolic biomarkers of heart failure	474
miRNA biomarkers of heart failure	474
Natriuretic peptide as biomarker of heart failure	474
Oxidative stress as biomarker of heart failure	475
Future prospects for biomarkers of heart failure	475
Biomarkers for atherosclerosis	475
9p21-3 locus and coronary atherosclerosis	475
Adipocyte enhancer-binding protein 1	476
Gene signatures on leucocytes as biomarkers of atherosclerosis	476
Ghrelin as a biomarker of atherosclerosis	477
Imaging biomarkers of hypercholesterolemia/atherosclerosis	477
Inflammatory biomarkers of atherosclerosis	477
Lipid-modified proteins as biomarkers of atherosclerosis	477
Lp-PLA2 as biomarker of atherosclerotic heart disease	477
Metabolomic profile in hypercholesterolemia	478
Nitric oxide impairment and atherosclerosis	478
Oxygen free radicals as biomarkers of atherosclerosis	478
Proteomic profiles of serum inflammatory biomarkers of atherosclerosis	478
Biomarkers of coronary heart disease	479
Apolipoproteins as risk factors for coronary heart disease	479
CRP as biomarker of risk for coronary heart disease	479
High level of blood ceramides as a biomarker of CHD	480
Impairment of EPCs by oxidative stress as a biomarker of disease	480
Role of TNF in acute coronary syndromes	481
Serum parathyroid hormone as biomarker of CHD	481
Serum stem cell factor as a biomarker of CHD	481
VILCAD biomarker score for prediction of long-term mortality in CHD	481
Biomarkers for pulmonary arterial hypertension	482
Biomarkers of abdominal aortic aneurysm	482
Biomarkers of thrombotic disorders	484
Biomarkers of arterial thromboembolism	484
Nanoparticles as synthetic biomarkers of thrombus formation	484
Biomarkers of venous thromboembolism	484
BNP and cTnT as biomarkers of outcome in pulmonary embolism	484
D-dimer as biomarker of venous thromboembolism	485
Molecular biomarkers of venous thromboembolism	485
Genetic biomarkers for cardiovascular disease	485
Biomarkers of inherited cardiomyopathies	485
Gene mutations in pulmonary arterial hypertension	485
Gene variant as a risk factor for sudden cardiac death	486
Genetic biomarkers of early onset myocardial infarction	486
Genetic biomarkers of atherosclerosis	486
IL-1 gene polymorphism as biomarker of cardiovascular disease	487
IL-6R signaling pathway and coronary heart disease	487
Kallikrein gene mutations in cardiovascular disease	487
Kallikrein gene and essential hypertension.	488
Mutations in the low density lipoprotein receptor gene	488
Mutations within several genes that code for ion channel	488
Polymorphisms of the eNOS gene and angina pectoris	489
Lipoprotein (a) genetics	489
Polymorphisms in the apolipoprotein C gene	489
Polymorphisms in the apolipoprotein E gene	490
Polymorphism in the angiotensinogen gene	490
Multiple biomarkers for prediction of death from cardiovascular disease	490
Role of biomarkers in the management of cardiovascular disease	491
Biomarkers in the diagnosis/prognosis of myocardial infarction	491
Biomarkers for prevention of cardiovascular disease	491
C reactive protein as biomarker of response to statin therapy	493
HSP72 and eNOS as biomarkers of cardioprotective effect of HBO	493
Multimarker panel for prognosis in chronic heart failure	494
Molecular signature analysis in management of cardiovascular diseases	494
Presage ST2 Assay	494
Role of circulating biomarkers and mediators of cardiovascular dysfunction	495
Use of protein biomarkers for monitoring acute coronary syndromes	495
Use of biomarkers for prognosis of recurrent atrial fibrillation	495

Use of multiple biomarkers for monitoring of cardiovascular disease	496
Use of biomarkers in the management of peripheral arterial disease.....	496
Use of biomarkers in the management of hypertension	496
Systems approach to cardiovascular biomarker research	497
16. Biomarkers of Pulmonary Diseases	499
Introduction.....	499
Association of biomarkers of inflammation with lung function in the elderly	499
Biomarkers of oxidative stress in lung diseases.....	500
Biomarkers of community-acquired pneumonia.....	500
Biomarkers of acute lung injury and respiratory distress syndrome	500
<i>Cytokine/chemokine biomarkers of SARS</i>	<i>500</i>
<i>Plasma biomarkers related to inflammation</i>	<i>501</i>
<i>Urinary NO as biomarker.....</i>	<i>501</i>
Biomarkers of interstitial lung disease	501
<i>Pulmonary surfactant proteins as biomarkers for lung diseases.....</i>	<i>501</i>
<i>Serum KL-6 as biomarker of interstitial lung disease</i>	<i>502</i>
Biomarkers of chronic obstructive pulmonary disease	502
<i>Alpha1-antitrypsin gene polymorphisms predisposing to emphysema</i>	<i>502</i>
<i>Biomarkers of extracellular matrix turnover in COPD</i>	<i>503</i>
<i>Biomarkers of lung failure in COPD.....</i>	<i>503</i>
<i>BNP as a biomarker of chronic pulmonary disease</i>	<i>503</i>
<i>Chromagranin A (CgA) as biomarker of airway obstruction in smokers.....</i>	<i>504</i>
<i>C-reactive protein as a biomarker of COPD.....</i>	<i>504</i>
<i>Gene expression profile in peripheral blood of patients with COPD.....</i>	<i>504</i>
<i>Hyperuricemia as a biomarker of early mortality in COPD.....</i>	<i>504</i>
<i>Increased expression of PIGF as a biomarker of COPD</i>	<i>504</i>
Biomarkers of asthma.....	505
<i>Biomarker for rhinovirus-induced asthma exacerbation</i>	<i>505</i>
<i>Biomarkers for predicting response to corticosteroid therapy</i>	<i>505</i>
<i>Comparison of biomarkers of asthma and COPD.....</i>	<i>505</i>
<i>Cytokines as biomarkers of asthma severity</i>	<i>506</i>
<i>Exhaled NO as a biomarker of asthma</i>	<i>506</i>
<i>Endothelin-1 in exhaled breath as biomarker of asthma</i>	<i>507</i>
<i>IgE as guide to dosing of omalizumab for asthma.....</i>	<i>507</i>
<i>Periostin as a biomarker for treatment of asthma with lebrikizumab</i>	<i>507</i>
Biomarkers of cystic fibrosis	508
17. Biomarkers in Gynecology and Obstetrics	509
Introduction.....	509
Biomarkers of menopause	509
Biomarkers of premenstrual dysphoric disorder	509
Biomarkers of endometriosis	510
Biomarkers for preeclampsia	510
Pathogenesis of preeclampsia	510
Metabolomic biomarkers in urine in preeclampsia.....	511
Protein biomarker of preeclampsia in urine.....	511
Protein biomarkers of preeclampsia in CSF	512
Protein HtrA1 as a biomarker for preeclampsia	512
Placental growth factor as a biomarker for preeclampsia	513
sFlt1 and soluble endoglin as biomarkers of preeclampsia	513
RNA biomarkers.....	513
Genes associated with preeclampsia	514
Biomarkers of premature birth	514
Proteomic biomarkers of premature birth	514
Biomarkers of oxidative stress in complicated pregnancies	515
Fetal biomarkers in maternal blood	515
Metabolic biomarkers of prenatal disorders in the mother.....	516
18. Biomarkers & Personalized Medicine	517
Introduction.....	517
Pharmacogenetics.....	517
Biomarkers and pharmacogenetics	518
Pharmacogenomics	519
Pharmacoproteomics	520
Single cell proteomics for personalized medicine	520
Role of biomarkers in development of personalized drugs.....	521
Metabolomic biomarker-based drug discovery.....	521
Use of biomarkers for developing MAb therapy in oncology	521
Biomarker tests for molecularly targeted therapies	522
Biobanking, biomarkers and personalized medicine in EU	523

Bioinformatics to sort biomarker data for personalized medicine	524
Biomarkers for monitoring response to therapy	525
Drug rescue by biomarker-based personalized medicine	525
Future role of biomarkers in personalized medicine	526

19. Biomarkers and Regulatory issues	527
Introduction.....	527
Biomarker validation.....	527
FDA criteria for a valid biomarker	527
FDA letter of support for biomarkers.....	529
Role of NIST in validation of cancer biomarkers	530
Quality specifications for BNP and NT-proBNP as cardiac biomarker assays	530
National Biomarker Development Alliance	530
FDA perspective of biomarkers in clinical trials	531
FDA and predictive medicine.....	532
Biomarkers and FDA’s Voluntary Genomic Data Submission	533
Role of imaging biomarkers in approval of drugs.....	533
Regulatory oversight of biomarker tests for targeted therapies	534
FDA and biomarkers.....	534
FDA consortium linking genetic biomarkers to serious adverse events	534
Oncology Biomarker Qualification Initiative	535
Critical Path Initiative	535
Predictive Safety Testing Consortium.....	537
The 21st Century Cures Act and biomarkers	537
From validated biomarker assay to a clinical laboratory diagnostic	538
Fast Path programs	539
Regulatory challenges in the biomarker field.....	539
FDA requirements of biomarkers and companion diagnostics	540
20. References.....	541

Tables

Table 1-1: Historical landmarks in discovery and development of biomarkers	30
Table 1-2: Classification of biomarkers	30
Table 1-3: Terminology of clinically relevant biomarkers of disease	32
Table 1-4: Autoimmune disorders under study for autoantibodies as predictors	42
Table 1-5: Comparison of various types of biomarkers	42
Table 1-6: Various “omics” technologies for discovery of biomarkers	44
Table 1-7: Role of biomarkers in translational medicine	45
Table 2-1: Classification of methods of gene expression analysis	48
Table 2-2: Comparison of proteomic profiling technologies for discovery of biomarkers	74
Table 2-3: Companies involved in developing molecular imaging	85
Table 3-1: Applications of biochip/microarray technology in relation to biomarkers	107
Table 4-1: Companies using metabolomics for drug discovery	121
Table 4-2: Biomarker-based drug development at major pharmaceutical companies	122
Table 4-3: Causes of failures in clinical trials and their reduction by use of biomarkers	125
Table 5-1: Metabolic biomarkers of inflammatory diseases.....	138
Table 5-2: Oxidized phospholipids as biomarkers of various diseases	139
Table 5-3: Examples of biomarkers common to multiple diseases	153
Table 5-4: Examples of use of biomarkers in animal health	155
Table 6-1: Biomarkers of diabetes mellitus	159
Table 8-1: miRNAs deregulated in rheumatoid arthritic tissues	179
Table 8-2: Classification of inflammatory biomarkers in osteoarthritis.....	182
Table 9-1: Biomarkers of sepsis.....	191
Table 11-1: Biomarkers of aging.....	208
Table 12-1: Nutritional biomarkers.....	217
Table 13-1: Desirable characteristics of biomarkers for cancer.....	224
Table 13-2: Types of cancer biomarkers	226
Table 13-3: A classification of molecular diagnostic methods in cancer	233
Table 13-4: Cancer biomarkers used for diagnosis and therapy	263
Table 13-5: Novel biomarkers of prognosis in cancer treatment.....	268
Table 13-6: Biomarkers of brain tumors	276
Table 13-7: Biomarkers of breast cancer	284
Table 13-8: miRNA associated with breast cancer	293
Table 13-9: Biomarkers of colorectal cancer	303
Table 13-10: Biomarkers of lung cancer	317
Table 13-11: Classification of biomarkers of melanoma	325
Table 13-12: Biomarkers of nasopharyngeal carcinoma and potential applications	327

Table 13-13: Biomarkers of ovarian cancer	329
Table 13-14: Classification of biomarkers of pancreatic cancer	335
Table 13-15: Biomarkers of prostate cancer	339
Table 14-1: Biomarkers of cerebral metabolism	360
Table 14-2: Classification of biomarkers of Alzheimer disease in blood and CSF	373
Table 14-3: Characteristics of an ideal biomarker for Alzheimer disease	375
Table 14-4: miRNA expression in neurodegenerative diseases	376
Table 14-5: Biomarkers of Parkinson disease	393
Table 14-6: Biomarkers of Huntington disease.....	399
Table 14-7: Classification of biomarkers of amyotrophic lateral sclerosis	401
Table 14-8: Biomarkers of multiple sclerosis	407
Table 14-9: Gene expression as biomarker of response to interferon- β in multiple sclerosis	411
Table 14-10: Biomarkers of stroke	416
Table 14-11: Etiological blood biomarkers of ischemic strokes due to large artery atherosclerosis	417
Table 14-12: Biomarkers of traumatic brain injury	427
Table 14-13: Biomarkers of epilepsy	434
Table 14-14: Biomarkers of autism spectrum disorder	444
Table 14-15: Biomarkers of response to antidepressant treatment.....	449
Table 14-16: Biomarkers of posttraumatic stress disorder.....	452
Table 15-1: Classification of biomarkers for cardiovascular diseases.....	458
Table 15-2: Genes that cause cardiovascular diseases	460
Table 15-3: Biomarkers of abdominal aortic aneurysm	483
Table 15-4: Biomarkers for cardiovascular disease risk prediction	491
Table 16-1: Biomarkers of pulmonary diseases.....	499
Table 18-1: Pharmacogenetic vs. pharmacogenomic studies	518
Table 18-2: Applications of pharmacoproteomic biomarkers in personalized medicine.....	520
Table 19-1: Issued letters of support for biomarkers by the FDA.....	529
Table 19-2: Drugs requiring biomarker/companion diagnostic information in the label.....	540

Figures

Figure 1-1: Relation of biomarkers to other technologies and healthcare.....	45
Figure 1-2: Role of biomarkers in monitoring of diseases	46
Figure 2-1: The central role of spectrometry in proteomics	57
Figure 2-2: Selected reaction monitoring workflow for verification of biomarkers	71
Figure 4-1: Role of biomarkers in drug discovery and development process	111
Figure 4-2: Onion-peel model of biomarker development.....	126
Figure 5-1: Diseases associated with myositis autoantibodies.....	154
Figure 6-1: Plasma lipids in metabolic syndrome.....	165
Figure 8-1: β -CrossLaps bone resorption biomarker assay	185
Figure 13-1: Role of proteomics in the discovery of cancer biomarkers	240
Figure 13-2: Nanowire biosensor for cancer diagnosis	256
Figure 13-3: Cancer biomarker development and validation	355
Figure 14-1: Discovery and application of biomarkers in neurological diseases	358
Figure 14-2: A scheme of pathogenesis of MDD with relevant biomarkers	448
Figure 15-1: Biomarkers of acute myocardial infarction related to pathophysiology	459
Figure 18-1: Role of pharmacogenetic biomarkers in personalized medicine	519
Figure 18-2: Workflow for developing metabolomics-based biomarkers for personalized treatment	521
Figure 18-3: Impact of biomarkers on personalized medicine	526
Figure 19-1: Stages and timelines of biomarker discovery, development and marketing	527
Figure 19-2: Biomarker qualification pilot process at the FDA	529
Figure 19-3: From a validated biomarker assay to a clinical laboratory diagnostic	538

Abbreviations

2D GE	2-dimensional gel electrophoresis
AD	Alzheimer's disease
BNP	B-type natriuretic peptide
CHD	coronary heart disease
CHF	congestive heart failure
CNS	central nervous system
CO	carbon monoxide
CRADA	cooperative research and development agreement (between a US federal laboratory and one or more non-federal parties)
CRP	C-reactive protein
CSF	cerebrospinal fluid
CT	computer tomography
CTC	circulating tumor cell
DT-MRI	diffusion-tensor MRI
EGFR	epithelial growth factor receptor
ELISA	Enzyme-linked immunosorbent assay
EST	expressed sequence tags
FDA	Food and Drug Administration, USA
FFPE	formalin-fixed paraffin-embedded
FISH	fluorescent in situ hybridization
fMRI	functional magnetic resonance imaging
GC	gas chromatography
GFAP	glial fibrillary acidic protein
GWAS	genome-wide association study
H ₂ S	hydrogen sulfide
Hs-CRP	high sensitivity C-reactive protein
IHC	Immunohistochemistry
IL	interleukin
KRAS	Kirsten rat sarcoma viral oncogene homolog
LC	liquid chromatography
LCM	laser capture microdissection
LDH	lactic dehydrogenase
LDT	Laboratory Developed Test

Lp-PLA2	lipoprotein-associated phospholipase A2
MALDI	matrix-assisted laser desorption/ionization
MALDI-MS	Matrix-Assisted Laser Desorption Mass Spectrometry
MCP-1	monocyte chemoattractant protein-1
miRNA	microRNA
MMR	mismatch repair
MRI	magnetic resonance imaging
MS	Mass spectrometry
mtDNA	mitochondrial DNA
NCI	National Cancer Institute
NIH	National Institutes of Health, USA
NMR	nuclear magnetic resonance
NO	nitric oxide
NRAS	neuroblastoma RAS viral (v-ras) oncogene homolog
NYHA	New York Heart Association
PCR	polymerase chain reaction
PET	positron emission tomography
PKC	protein kinase C
POC	point-of-care
PPAR	peroxisome proliferator-activator receptor
PSA	prostate-specific antigen
PSMA	prostate-specific membrane antigen
RAS	rat sarcoma viral oncogene homolog
RCAT	Rolling circle amplification technology
RNAi	RNA interference
SELDI-TOF	surface-enhanced laser desorption and ionization-time of flight
sICAM-1	soluble intercellular adhesion molecule-1
SNP	single nucleotide polymorphisms
SPR	surface plasma resonance
TIMI	Thrombolysis In Myocardial Infarction
USPTO	United States Patent & Trademark Office